6-26-2021

Preoperative CA 19-9 Level as Additional Predictor of Pancreatic Head Adenocarcinoma Resectability

Pasihulizan Pasihulizan  
*Department of Surgery, Faculty of Medicine Universitas Indonesia, pasihulizan@gmail.com*

Agi S. Putranto  
*Department of Surgery, Faculty of Medicine Universitas Indonesia, agi_digestive@yahoo.com*

Follow this and additional works at: [https://scholarhub.ui.ac.id/nrjs](https://scholarhub.ui.ac.id/nrjs)

Part of the **Gastroenterology Commons**, **Oncology Commons**, and the **Surgery Commons**

**Recommended Citation**

Pasihulizan, Pasihulizan and Putranto, Agi S. (2021) "Preoperative CA 19-9 Level as Additional Predictor of Pancreatic Head Adenocarcinoma Resectability," *The New Ropanasuri Journal of Surgery*. Vol. 6 : No. 1 , Article 1.  
DOI: 10.7454/nrjs.v6i1.1099  
Available at: [https://scholarhub.ui.ac.id/nrjs/vol6/iss1/1](https://scholarhub.ui.ac.id/nrjs/vol6/iss1/1)

This Article is brought to you for free and open access by the Faculty of Medicine at UI Scholars Hub. It has been accepted for inclusion in The New Ropanasuri Journal of Surgery by an authorized editor of UI Scholars Hub.
Preoperative CA 19-9 Level as Additional Predictor for Resectable Pancreatic Head Adenocarcinoma

Agi S. Putranto

Department of Surgery, Faculty of Medicine Universitas Indonesia

Introduction. Determining eligibility criteria for resection is the basis of pancreatic head adenocarcinoma treatment planning, yet the currently used CT scan only has 80% accuracy as its primary modality. This study aimed to investigate preoperative CA 19-9 level use to help predict resectability of pancreatic head adenocarcinoma.

Method. Determining eligibility criteria for resection is the basis of pancreatic head adenocarcinoma treatment planning, yet the currently used CT scan only has 80% accuracy as its primary modality. This study aimed to investigate preoperative CA 19-9 level use to help predict resectability of pancreatic head adenocarcinoma.

Results. There were 54 subjects enrolled in the study, with the Mean age of both unresectable and resectable subjects is 53.78±11.13 years. Twenty-nine were assigned as an unresectable group and 25 subjects as a resectable group. We found significant differences in CA 19-9 serum albumin levels and Kamofsky score between the resectable and unresectable groups. The cut-off point for CA 19-9 levels was 140.65 U/mL, with a sensitivity of 82.76% (64.23% - 94.15%), specificity of 72.00% (50.61% - 87.93%), and AUC of 0.784.

Conclusion. CA 19-9 was significantly associated with eligibility criteria for pancreatic head carcinoma resection. CA 19-9 has a high diagnostic value as an additional predictor for resectable pancreatic head carcinoma.

Key words: CA 19-9, eligibility criteria for resection, resectable pancreatic head adenocarcinoma
charge, histopathological findings, and surgery chosen by surgeons in charge.

All numeric variable was evaluated for distribution normality using Kolmogorov-Smirnov Test. Bivariate analysis tests were conducted according to data type and distribution normality using the Unpaired T/Mann-Whitney test between resectable and unresectable pancreatic head adenocarcinoma groups. We carried out further diagnostic analysis for CA 19-9 levels, and the ROC curve was used to determine the cutoff point. A Chi-square test was used for this purpose. Bias control was done using multivariate logistic regression analysis of factors with p <0.25 on bivariate analysis.

This study approved by Ethical Committee of Faculty of Medicine, Universitas Indonesia, No. KET-1222/F1/ETIK/PPM.00.02/2020.

Results

Patient characteristics and diagnostics modalities findings bivariate analysis

This study included 54 subjects diagnosed with pancreatic head adenocarcinoma enrolled in dr. Cipto Mangunkusumo General Hospital through 2016-2020. Twenty-nine subjects were assigned as an unresectable and 25 subjects as a resectable group through CT scan imaging. Demographic characteristics, surgical approach is chosen; laboratory, imaging, and histopathological findings of subjects are shown in Table 1. The mean age of both unresectable and resectable subjects is 53.78±11.13 years old.

Table 1. Characteristics of subjects with pancreatic head adenocarcinoma in the study

|                        | Unresectable (n= 29) | Resectable (n= 25) | p        |
|------------------------|----------------------|-------------------|----------|
| Age (mean ± SD)        | 53.83±10.89          | 53.72±11.62       | 0.851    |
| Gender [n (%)]         |                      |                   |          |
| Male                   | 17 (58.62%)          | 13 (52%)          | 0.625    |
| Female                 | 12 (41.38%)          | 12 (48%)          |          |
| Weight in kg (mean ± SD) | 53.98±12.39        | 54.52±8.64        | 0.277    |
| Height in kg (mean ± SD) | 162.55±7.14        | 160.40±7.22       | 0.972    |
| Karnofsky score [median (min–max)] | 80 (50–100)    | 100 (60–100)      | <0.001   |
| BMI [n (%)]            |                      |                   | 0.003    |
| Underweight            | 14 (48.28%)          | 2 (8%)            |          |
| Normoweight            | 14 (48.28%)          | 22 (88%)          |          |
| Overweight             | 1 (3.45%)            | 1 (4%)            |          |
| Diabetes Mellitus [n (%)] | 2 (6.70%)         | 4 (16%)           | 0.399    |
| Scored SGA [n (%)]     |                      |                   | <0.001   |
| A: well-nourished      | 6 (20.69%)           | 20 (80%)          |          |
| B: mild/moderately-nourished | 19 (65.52%)  | 3 (12%)           |          |
| C: severely malnourished | 4 (13.79%)         | 2 (8%)            |          |
| Bilirubin in mg/dL [median (min–max)] | 7.02 (0.33–31.21) | 7.40 (0.34–30.00) | 0.938  |
| Total                  | 5.40 (0.17–22.40)   | 5.40 (0.20–24.90) | 0.896    |
| Direct                 | 1.18 (0.12–8.81)    | 2.08 (0.10–17.20) | 0.299    |
| Indirect               |                      |                   |          |
| CA 19-9 level in U/mL [median (min–max)] | 421.9 (25.75–42.648) | 65 (12–12.000) | <0.001 |
| Albumin in g/dL [median (min–max)] | 3.00 (2.30–4.90) | 3.37 (2.53–4.41) | 0.030   |
| Vascular involvement [n (%)] | 10 (34.48%) | 23 (92%) |          |
| No involvement         | 10 (34.48%)          | 23 (92%)          |          |
| SMV                    | 10 (34.48%)          | 2 (12%)           |          |
| SMA                    | 3 (10.34%)           | 0                 | <0.001   |
| CHA                    | 1 (3.45%)            | 0                 |          |
| CT                     | 1 (3.45%)            | 0                 |          |
| SMA + SMV              | 3 (10.34%)           | 0                 |          |
| Metastasis [n (%)]     | 14 (48.28%)          | 0                 | <0.001   |
| Surgery [n (%)]        |                      |                   |          |
| Biliary stent only     | 11 (37.93%)          | 8 (32%)           |          |
| Whipple                | 0                    | 10 (40%)          |          |
| Hepaticejunostomy bypass | 1 (3.45%)      | 1 (4%)            |          |
| Double bypass          | 5 (17.24%)           | 2 (8%)            | 0.301    |
| Biliary + chemotherapy | 3 (10.34%)           | 2 (8%)            |          |
| PTBD                   | 1 (3.45%)            | 1 (4%)            |          |
| Metal stent + gastrojejunostomy | 7 (24.14%) | 0 |          |
| Cholecystostomy        | 0                    | 1 (4%)            |          |
| Histopathological findings [n (%)] | 21 (72.41%) | 17 (68%) |          |
| Adenocarcinoma         |                      |                   |          |
| Well-differentiated    | 6 (20.69%)           | 6 (24%)           | 0.696    |
| Moderately differentiated | 2 (6.90%)      | 0                 |          |
| Poorly differentiated  | 0                    | 2 (8%)            |          |

Abbreviations: BMI= Body Mass Index, SGA= Subjective Global Assessment based on Canadian malnutrition task force (CMTF), SMV= Superior mesenteric vein, SMA= Superior mesenteric artery, CHA= Common hepatic artery, CA= Celiac artery, PTBD= Percutaneous transhepatic biliary drainage.
Bivariate analysis showed significant difference between unresectable and resectable groups for CA 19-9 (p <0.001), Karnofsky score (p <0.001), BMI (p = 0.003), SGA score (p <0.001), serum albumin (p = 0.030), vascular involvement (p <0.001), and metastasis (p <0.001). These variables were then included in multivariate logistic regression analysis for bias control, except for vascular involvement and metastasis, as these parameters were used as a gold standard basis in assigning groups for subjects. Before multivariate analysis, numerical variables (albumin and Karnofsky score) were dichotomized using the area under the curve (AUC)-ROC curve to find the cutoff level. The result was 3.025 g/dL optimum level of albumin (sensitivity of 76% and specificity of 62.1%) and 85 values cut off for Karnofsky score (sensitivity of 80% and specificity of 69%).

Preoperative CA 19-9 levels and eligibility criteria for pancreatic head adenocarcinoma resection

This study recorded a 2698.40 ± 6843.33 U/mL mean level of CA 19-9 with some outlier data. The preoperative CA, 19-9 level of study subjects, are shown in Table 1, in which bivariate analysis using Mann-Whitney test showed significant difference for CA-19-9 level between resectable and unresectable group (p <0.001). We developed a ROC curve to find the AUC value and determine the CA-19-9 cutoff level with optimum sensitivity and specificity to predict resectable pancreatic head adenocarcinoma, as shown in Figure 1. The study found 0.784 AUC (SD = 0.065; CI (95%) = 0.656-0.912; p <0.001). ROC curve showed the CA-19-9 cutoff level was 140.65 U/mL with the sensitivity of 82.76% (64.23%-84.15%) and specificity of 72.00% (50.61%-87.93%) as described in Table 2.

Table 2. Diagnostic Value of CA 19-9 level on 140.65 U/mL threshold as additional eligibility criteria for pancreatic head adenocarcinoma resection

| Parameter          | Value (U/mL) | CI (95%)         |
|--------------------|--------------|-----------------|
| Sensitivity        | 82.76%       | 64.23%-94.15%   |
| Specificity        | 72.00%       | 50.61%-87.93%   |
| Positive predictive value | 77.42% | 64.15%-86.79%   |
| Negative predictive value | 78.26% | 60.99%-89.23%   |
| Positive likelihood ratio | 2.96 | 1.54-5.66     |
| Negative likelihood ratio | 0.24 | 0.10-0.55     |

Further analysis found the difference between preoperative CA 19-9 between unresectable and resectable pancreatic head adenocarcinoma groups using the determined optimum CA 19-9 cut-off level. The Chi-square test showed a significant difference between the resectable and unresectable groups, as shown in Table 3.

Table 3. Proportion analysis of CA 19-9 between resectable and unresectable group

| CA 19-9 (U/mL) | Unresectable n (%) | Resectable n (%) | OR (CI95%) | P     |
|----------------|---------------------|------------------|------------|-------|
| ≥140.65        | 24 (82.76)          | 7 (14)           | 12.34      | 0.000*|
| <140.65        | 5 (17.24)           | 18 (76)          | (3.4-45.3) |       |

Total           | 29                  | 25                |            |       |

*Chi-square test

Discussion

Subject Characteristics

This study found a statistically significant difference in Karnofsky score, BMI, SGA score, and albumin value. This finding may be related to the eligibility criteria for pancreatic head adenocarcinoma resection affected by malignancy stages, which would directly affect these factors. We also found elevated bilirubin levels in 86% of patients caused by CBD compression on the first stages of pancreatic head adenocarcinoma. Out of 25 resectable patients, only 10 (40%) could receive tumor resection procedure (Whipple procedure). This number may be related to the fast progression of adenocarcinoma and negative biliary drainage response, explaining why 60% of patients whose predicted as resectable through radiological modality were deemed inoperable before surgery.

Diagnostic value of CA 19-9 to predict resectable pancreatic head adenocarcinoma

Prior studies had shown the potentials of preoperative CA 19-9 level as prognostic predictor pancreatic adenocarcinoma, as Dong et al.14 found >338.45 U/mL CA 19-9 level predicted a low one-year survival rate with a sensitivity of 60% and specificity of 66.7%. Following prognostic predictions, eligibility criteria for pancreatic head adenocarcinoma resection depend on adenocarcinoma cells infiltration to nearby tissue, in which a higher rate of infiltration would be reflected by a higher level of CA 19-9. This study demonstrated that CA 19-9 level could predict resectable pancreatic head adenocarcinoma accuracy up to the appropriate category.13,15

This result was contradictory with Pandiaraja et al.4 study, which mentioned no relationship between CA 19-9 level and resectable pancreatic head adenocarcinoma; but Pandiaraja et al. used 37 U/mL CA 19-9 level as the optimum level, which was much lower than the optimum CA 19-9 level used in our study. Their study also failed to mention the obtained sensitivity and specificity from their analysis. Our study result was supported by other studies, such as Killic et al. [6] that found 256.4 U/mL CA 19-9 cut-off level with 82.4% sensitivity, 92.3% specificity, and 0.892 AUC. We believe the variation of sensitivity, specificity, and AUC value with our study was caused by the difference in patients’ characteristics.

There haven’t been many studies that evaluated CA 19-9 diagnostics values, as most studies focused on elevating the accuracy of CT scans. The use of CT scan is deemed easier and more efficient, but it should be noted that the availability of CT scan in Indonesia is scarce, so a more straightforward method using laboratory findings remains needed.

Multivariate analysis with logistic regressions

Different characteristics of patients may contribute to the interpretation of diagnostic modalities result, and there may be some confounding factors that work against the interpretation of the diagnostics modalities’ sensitivity, specificity, and AUC value. We included various dependent variables other than CA 19-9 levels to test this possibility and found...
Karnofsky score and albumin levels to affect resectable pancreatic head adenocarcinoma prediction. We tried to combine these factors with CA 19-9 levels and found elevated diagnostic value for CA 19-9 levels into an excellent category when combined with Karnofsky score and albumin levels. Although the Karnofsky score is a clinical indicator and albumin has no specific link with the natural history of pancreatic head adenocarcinoma, both variables are commonly used to predict adequate physical condition before surgery and contributed to predicting operability. Thus, we believe these factors could be potential predictors of a patient's clinical prognosis post-surgery. No study has examined this possibility yet, and further study is needed to understand these variables' value as additional eligibility criteria for pancreatic head adenocarcinoma resection.  

**Conclusion**

There was a significant association between preoperative CA 19-9 and eligibility criteria for pancreatic head adenocarcinoma resection. There was also a significant difference in albumin levels and Karnofsky scores between the resectable and unresectable groups. Further studies with more samples from different healthcare settings are needed to evaluate CA 19-9 levels' prognostic values and possibly use combined indicators with albumin level and Karnofsky score.

**Disclosure**

Authors declare no conflict of interest.

**References**

1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019;10(1):10–27.
2. Globocan. Incidence, mortality, and prevalence by cancer site in Indonesia [Internet]. 2018. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf
3. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: State-of-the-art care. Ca-Cancer J Clin. 2000;50(4):241–68.
4. Pandiaraja J, Viswanathan S, Antony TB, Thirumuruganand S, Kumaresan DS. The Role of CA19-9 in Predicting Tumour Resectability in Adenocarcinoma Head of Pancreas. J Clin Diagn Res JCDR. 2016;10(3):PC06–9.
5. Wiguna KA, Sudartana K, Golden N. Validitas nilai CA 19-9 praoperatif dalam memprediksi resektabilitas pada kejadian karsinoma pankreas. Intisis Sains Medis [Internet]. 1 April 2019 [cited 6 July 2020];10(1). Available from: https://issainsmedis.id/index.php/ism/article/view/340
6. Kiliç M, Göçmen E, Tez M, Ertan T, Keskek M, Koç M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg. 2006;49(4):241–4.
7. Kim CB, Ahmed S, Hsueh EC. Current surgical management of pancreatic cancer. J Gastrointest Oncol. 2011;2(3):126–35.
8. Griffin JF, Poruk KE, Wolfgang CL. Pancreatic cancer surgery: past, present, and future. Chin J Cancer Res. 2015;27(4):332–48.
9. Santucci N, Facy O, Ortega-Deballon P, Lequeux J-B, Rat P, Rat P. CA 19–9 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology. 2018;18(6):666–70.
10. Ritts RE, Pitt HA. CA 19-9 in Pancreatic Cancer. Surg Oncol Clin. 1998;7(1):93–101.
11. Irmayanti, Bahrun U, Parewangi AL, Samad IA. Penanda tumor untuk diagnosis karsinoma kaput pankreas. CDK-26. 2018;45(3):207–9.
12. Rückert F, Pilsarzky C, Gritzmann R. Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries. Cancers. 2010;2(2):1107–24.
13. Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3(2):105–19.
14. Dong Q, Yang X, Zhang Y, Jing W, Zheng L, Liu Y, dkk. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12:171.
15. Safari S, Baratloo A, Elfil M, Negida A. Evidence Based Emergency Medicine; Part 5 Receiver Operating Curve and Area under the Curve. Emergency. 2016;4(2):111–3.
16. Wu B-W, Yin T, Cao W-X, Gu Z-D, Wang X-J, Yan M, et al. Clinical application of subjective global assessment in Chinese patients with gastrointestinal cancer. World J Gastroenterol WJG. 2009;15(28):3542–9.